59 min

Non-Small Cell Lung Cancer | Meet The Professor: Non-Small Cell Lung Cancer with an Actionable Target Beyond EGFR — Part 1 Research To Practice | Oncology Videos

    • Science

Featuring perspectives from Dr Ross Camidge, including the following topics:
Introduction: First-line systemic treatment; brain metastases (0:00) Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30) Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44) Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26) Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01) Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43) Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09) Treatment for Patients with ROS1 Fusions (48:34) RET Fusions in Lung Cancer (52:38) BRAF Mutations (54:20) NRG Fusions (55:31) CME information and select publications

Featuring perspectives from Dr Ross Camidge, including the following topics:
Introduction: First-line systemic treatment; brain metastases (0:00) Case: A woman in her early 60s with squamous NSCLC metastatic to tbe brain and an ALK rearrangement; PD-L1 TPS 70% — Spencer Henick Bachow, MD (20:30) Case: A man in his early 70s with localized NSCLC with an ALK rearrangement and significant comorbidities — Sunil Gandhi, MD (24:44) Case: A woman and heart transplant recipient in her mid 70s with metastatic NSCLC with a KRAS G12C mutation; PD-L1 TPS 20% — Mamta Choksi, MD (30:26) Case: A woman in her late 70s with metastatic NSCLC and a MET exon 14 skipping mutation — Jennifer L Dallas, MD (36:01) Case: A woman in her late 60s with metastatic NSCLC and a HER2 exon 19 mutation pathogenic variant; PD-L1 TPS 15% — Rajni Sinha, MD, MRCP (41:43) Case: A man in his early 30s with metastatic NSCLC and an NTRK fusion; PD-L1 TPS 10% — Daniel R Carrizosa, MD, MS (46:09) Treatment for Patients with ROS1 Fusions (48:34) RET Fusions in Lung Cancer (52:38) BRAF Mutations (54:20) NRG Fusions (55:31) CME information and select publications

59 min

Top Podcasts In Science

Jordan Harbinger
Hidden Brain
Alie Ward
Vox
Sam Harris
PRX and Greater Good Science Center

More by Research To Practice

Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love
Dr Neil Love